Retatrutide 10MG

Retatrutide (LY3437943) is an investigational once-weekly triple hormone-receptor agonist engineered by Eli Lilly. It is the first molecule to combine agonism at all three incretin-related receptors — GLP-1, GIP, and glucagon — in a single 39-amino-acid backbone stabilized by a C20 fatty-diacid side chain that extends plasma half-life to ~6 days. Reported research benefits: substantial reductions in body weight (mean 24.2% at 12 mg by week 48 in the Phase 2 NEJM trial, 2023), improved glycemic control and HbA1c reductions in type 2 diabetes models, decreased visceral and hepatic fat, elevated resting energy expenditure through glucagon-driven thermogenesis, improvements in blood pressure and lipid panels (LDL, triglycerides, ApoB), and appetite suppression with reduced caloric intake. Neurpex supplies research-grade material for preclinical model work only.